Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

1 Feb 2023

Abstract excerpt

Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy. Isocitrate dehydrogenases (IDHs) are a class of key proteins in energy metabolism, including IDH1, IDH2, and IDH3, which are involved in the oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG). Mutants of IDH1 or IDH2 can produce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37139412
DOI: 10.1016/j.apsb.2022.12.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerPMID 37139412Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

The roles of IDH1 in tumor metabolism and immunity.Semantic proximity Read ↗

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Semantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.Semantic proximity Read ↗

Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.Semantic proximity Read ↗

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Semantic proximity Read ↗

Comprehensive exploration of isocitrate dehydrogenase (IDH) mutations: Tumorigenesis, drug discovery, and covalent inhibitor advances.Semantic proximity Read ↗

Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.